FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma

Table 1 Patient characteristics

Characteristics	Patients (n)
Median age (range) (yr)	60 (39-72)
Sex
Male	6
Female	7
ECOG performance status
0	3
1	8
2	2
Median CA 19-9 level (range) (ng/mL)	73 (2-4472)
Previous chemotherapy
Intravenous gemcitabine oxaliplatin	13
Intra-arterial gemcitabine oxaliplatin	5
Tumor limiting the liver
Yes	4
No	9

ECOG: Eastern Cooperative Oncology Group; CA 19-9: Carbohydrate antigen 19-9.

Table 2 Observed toxicity according National Cancer Institute Common Terminology Criteria for adverse events grading (n = 12)

	NCI-CTC grade
	All grades	Severe1
Hematological
Anemia	5	0
Neutropenia	7	3
Thrombocytopenia	6	2
Non hematological
Nausea/vomiting	6	0
Mucositis	1	0
Diarrhea	5	2
Infection	0	0
Nose bleeding	2	0
High blood pressure	2	0

¹Grade 3-4 according to the National Cancer Institute Common Terminology Criteria for adverse events (NCI-CTC) version 2.0 scale.